The Food and Drug Administration (FDA) is aware of a safety issue regarding the drug rosiglitazone maleate, marketed under the brand name Avandia. The drug is for type 2 diabetes.
Safety data analysis of controlled clinical trials shows a significant increase in the risk of heart attack and heart related health issues and deaths in patients that take Avandia.
Published and unpublished data from long term clinical trials provides a contradictory argument about the risk of heart related health problems in patients taking Avandia.
The FDA’s review of data is still ongoing. The FDA is yet to confirm the significance of the reported increase risk of heart risks in context to other such studies.